Conexeu Sciences Raises Fresh Funding For Planned FDA Submission

Mentioned:

Conexeu Sciences has just raised a new financing round. And they’re planning to use it to prepare for their first ever submission to the United States Food and Drug Administration.

What’s happening:

Conexeu Sciences (NASDAQ: CNXU) has successfully raised $5M USD in a new equity financing round

Why it matters:

Conexeu Sciences will use the new growth capital to advance their manufacturing scale up and regulatory testing ahead of their planned 510(k) submission to the United States Food and Drug Administration for their lead wound care device candidate known as Ten Minute Tissue

Going deeper:

Conexeu Sciences is aiming to position their proprietary CXU platform for medical aesthetics and facial and body tissue restoration in addition to wound care
Conexeu Sciences successfully completed a 12 month preclinical trial that demonstrated their CXU platform met its objective for tissue restoration in a facial model and is designed to be delivered through a fine-gauge needle for precise placement to support the tissue changes that can follow GLP-1 weight loss, including both facial volume loss as well as skin laxity

The intrigue:

McKinsey publicly stated in a research report that 63% of patients seeking facial aesthetics after GLP-1 weight loss were not previously active users of medical aesthetic treatments

Disclaimer

The New Money provides background information on early stage companies from publicly available sources. The New Money provides no advice on dealing in securities, is not a financial adviser and does not pretend to be so. This message is meant for information and educational purposes only. The information contained in this article is not to be considered factual or complete. Anybody interested in obtaining financial and other information on companies mentioned is advised to get it direct from the companies, or from their own investment adviser. The New Money does not intend for this information to be used to inform an investment decision.

The New Money has been compensated by Conexeu Sciences for a media campaign, which affects our ability to be unbiased. The Principals of The New Money may buy or sell shares of the company without further notice. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities. The New Money and its principals and agents are not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Always do your own research and consult with a licensed investment professional before making an investment.

This communication should not be used as a basis for making any investment. Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy or Sell securities. No representation is being made that any stock trade will or is likely to achieve profits. Comparisons made to other featured companies or past performance is not indicative of future results.